A case of thyrotoxicosis in a patient bearing a thyroid carcinoma with lymph node and bone metastases is described. The I131 uptake of the thyroid was notably low (8 % at 24 hours) and was not modified by TSH. Some of the bone metastases showed a high I131 uptake; the PBI was elevated. In this case, the pathogenesis of the thyrotoxicosis is not explained by the common hypotheses; the authors suggest that it might be explained with a reduced metabolisation of the thyroid hormones.
Get full access to this article
View all access options for this article.
References
1.
BlackB. M., WoolnerL. B., and BlackburnCh. Mn.: The uptake of radioactive iodine by carcinoma of the thyroid gland.J. Clin. Endocrinol3: 1378–1390, 1953.
2.
ChiariottiF.: Alcuni singolari aspetti delle neoplasie tiroidee.Radiol Med46: 738–756, 1960.
3.
CunninghamR. M., HiltonG., and PochinE. E.: Radioiodine uptake in thyroid carcinomata.Brit. J. Radiol., 28: 252–256, 1955.
4.
DeissW. P., O’ ShaugnessyP. Y., and WynnJ. O.: Early effects of thyrotropin on protein-bound iodine 131 and plasma iodine-131.J. Clin. Invest., 38: 334–341, 1959.
EiselsbergA.: Ueber Knochenmetastasen des Schilddrusenkrebses.Arch. Klin. Chir., 46: 430–443, 1893.
7.
EiselsbergA.: Ueber physiologische Funktion einer in Sternum zur Entwickelung gekommenen krebsigen Schilddrusenmetastase.Arch. Klin. Chir., 48: 489–501, 1894.
8.
GinsburgE., CatzB., and NelsonC. L.: Hyperthyroidism secondary to metastatic functioning thyroid carcinoma.Am. Int. Med., 58: 684–690, 1963.
9.
HertzJ.: Functioning late metastases from thyroid carcinoma.Acta path. Microbiol. Scandin., 105: 60–91, 1955.
10.
HolstJ.: Weitere beitrage zur Pathologie und Therapie der toxischen Strumen.Acta Chir. Scandinav., 61: 385–442, 1927.
11.
HuntW. B., CrispellK. R., and Mc KeeJ.: Functioning metastatic carcinoma of the thyroid producing clinical hyperthyroidism.Amer. J. Med., 28: 995–1001, 1960.
12.
LeiterL., SeidlinS. M., MarinelliL. D., and BaumanE.: Adenocarcinoma of the thyroid with hyperthyroidism and functional metastates.J. Clin. Endocrinol., 6: 247–261, 1946.
13.
MalamosB., MoirasK., SamaraB., und LevisG.: Serum-Thyroxin und Trijodthyronin bei funktionierendem Schilddrüsen-Carcinom.Klin. Wschr., 39: 255–257, 1961.
14.
MilaniF., VoltaA., e MarinoniU.: Frazioni ormonali tiroidee nel plasma in varie condizioni.Arch. Patol. Clin. Med., 37: 345–356, 1961.
15.
RocheJ., et MichelR.: Hormones thyroidiennes et jodoproteines naturelles ou artificielles jodées.Actualités pharmacologiques, VI serie, 1953, Masson Ed.
16.
StuderH., VeragutP., and WyssF.: Thyrotoxicosis due to a solitary hepatic metastasis of thyroid carcinoma.J. Clin. Endocrin., 21: 1334–2681, 1962.
17.
TrunnellJ. B., MarinelliL. D., DuffyJr., and HillR. J.: The treatment of metastatic thyroid cancer with radioactive iodine: credits and debits.J. Clin. Endocrinol., 9: 1138–1152, 1949.
18.
WegelinC.: Malignant disease of the thyroid gland and its relations to goitre in man and animals.Cancer Rev., 3: 297–313, 1928.
